---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Generic, brand name and therapeutic class of product. Topics: Generic name, chemical name, and identifiers; Development codes: MLS-101 and MT-4129; Manufacturer: Mineralys Therapeutics; Originator and license: Tanabe Pharma Corporation; 1 further topic. 5 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Generic name, chemical name, and identifiers

| Field | Quoted record |
| --- | --- |
| International nonproprietary name (Latin) | “lorundrostatum” |
| International nonproprietary name (English) | “lorundrostat” |
| Functional description | “aldosterone synthase inhibitor” |
| Molecular formula | “C24H33N7O2” |
| CAS registry number | “1820940-17-7” |

Source: [WHO Drug Information (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl127.pdf)

> “N-(trans-4-acetamidocyclohexyl)-2-{4-[5-(4-”
> “methylphenyl)-1,2,4-triazin-3-yl]piperazin-1-”

Source: [WHO Drug Information (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl127.pdf)

<a id="topic-2.1.2.1-2"></a>

### Development codes: MLS-101 and MT-4129

> “A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

> “A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

> “pursuant to which Tanabe granted the Company an exclusive, worldwide, royalty-bearing, sublicensable license under Tanabe’s patent and other intellectual property rights to exploit products incorporating lorundrostat (formerly MT-4129) (Lorundrostat Product)”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.2.1-3"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

### Manufacturer: Mineralys Therapeutics

> “Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

> “We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.2.1-5"></a>

### Originator and license: Tanabe Pharma Corporation

> “We licensed lorundrostat from Tanabe Pharma Corporation (Tanabe), which discovered the compound and provided the early foundational work, including demonstrating the selectivity of lorundrostat, and progressing the asset through Phase 1 clinical development.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “On June 2, 2026, the Company entered into a fourth amendment to the Tanabe License (the Fourth Amendment), pursuant to which the Company’s obligation to pay Tanabe royalties on net sales of Lorundrostat Products was terminated, the license was amended and restated to grant the Company an exclusive, worldwide, royalty-free, sublicensable, perpetual, irrevocable license,”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

> “Tanabe has also agreed to subsequently assign to Mineralys its intellectual property rights related to lorundrostat.”

Source: [Mineralys Therapeutics press release, Tanabe royalty repurchase (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/104/mineralys-therapeutics-announces-repurchase-of-royalty)

| Field | Quoted record |
| --- | --- |
| Lead sponsor of the first-in-human study | “Tanabe Pharma Corporation” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-2.1.2.1-6"></a>

### Therapeutic class: oral, highly selective aldosterone synthase inhibitor

> “Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
